Skip to main content
Premium Trial:

Request an Annual Quote

UnitedHealthcare Agrees to Cover Paradigm Cancer Diagnostic

NEW YORK (GenomeWeb) – Molecular diagnostics developer Paradigm announced today that it has reached an agreement with UnitedHealthcare for insurance coverage of its next-generation sequencing-based cancer diagnostic test PCDx.

The diagnostic is designed to identify the genomic and proteomic alterations underlying a patient's tumor DNA, RNA, and proteins, leading to a more personalized and targeted approach to treatment.

"We continue to make excellent progress in our discussions with provider networks to ensure our best-in-class NGS test is available to the millions of Americans who are suffering with cancer," Paradigm CEO Robert Penny said in a statement. "With this contract, millions of patients and their treating clinicians will have access to our leading oncology testing service and make possible more informed and individually tailored treatment strategies."

Paradigm has signed similar coverage agreements with other insurers in recent months, including Atlanta-based Stratose in July and the Three Rivers Provider Network in August.